About regenxbio inc - RGNX
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
RGNX At a Glance
REGENXBIO, Inc.
9804 Medical Center Drive
Rockville, Maryland 20850
| Phone | 1-240-552-8181 | Revenue | 170.44M | |
| Industry | Pharmaceuticals: Major | Net Income | -193,878,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 104.542% | |
| Fiscal Year-end | 12 / 2026 | Employees | 371 | |
| View SEC Filings |
RGNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.357 |
| Price to Book Ratio | 7.133 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.31 |
| Enterprise Value to Sales | 4.536 |
| Total Debt to Enterprise Value | 0.337 |
RGNX Efficiency
| Revenue/Employee | 459,409.704 |
| Income Per Employee | -522,582.21 |
| Receivables Turnover | 6.224 |
| Total Asset Turnover | 0.371 |
RGNX Liquidity
| Current Ratio | 2.382 |
| Quick Ratio | 2.382 |
| Cash Ratio | 1.948 |
RGNX Profitability
| Gross Margin | 78.929 |
| Operating Margin | -94.577 |
| Pretax Margin | -113.751 |
| Net Margin | -113.751 |
| Return on Assets | -42.192 |
| Return on Equity | -107.001 |
| Return on Total Capital | -53.373 |
| Return on Invested Capital | -57.487 |
RGNX Capital Structure
| Total Debt to Total Equity | 253.587 |
| Total Debt to Total Capital | 71.718 |
| Total Debt to Total Assets | 57.505 |
| Long-Term Debt to Equity | 206.967 |
| Long-Term Debt to Total Capital | 58.533 |